VIRX: Viracta Price-to-Revenue Coefficient
Viracta Therapeutics develops cutting-edge oncology drugs whose global expansion is secured by robust patent protection. The brand is valued for its precision method of combating lymphomas through the activation of viral genes. Currently, the company is developing a line of agents against the Epstein-Barr virus based on the "kick and kill" principle. The volatility of the P/S ratio clearly demonstrates the market valuation, while the indicator reflects the current dynamics.
Viracta Therapeutics (VIRX) - metric breakdowns and financial figures
- current price and projected stock value:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Viracta Therapeutics|VIRX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Viracta Therapeutics, Inc.|VIRX - Company Aggregate Debts|Debts to Book Capitalization Viracta Therapeutics, Inc.|VIRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Viracta Therapeutics|Intermediate Liquidity Ratio viracta.com
- earnings and valuation multiples information:
VIRX - Net Profit|Expected Net Income Viracta Therapeutics|VIRX - P/E Multiple|Projected Price to Earnings Ratio Viracta Therapeutics Inc.|VIRX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Viracta Therapeutics, Inc.|VIRX - Operating profit EBITDA|Net earnings per share (EPS TTM) Viracta Therapeutics|VIRX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months viracta.com|VIRX - Earnings growth in current year|Expected net earnings per share growth next year Viracta Therapeutics
- issuer revenue and sales details:
General company analysis:VIRX viracta.com
The P/S multiple compares a business's market value to its annual sales volume, making it possible to determine the premium paid per unit of revenue. Analyzing the price/sales multiple of Viracta Therapeutics (VIRX) helps identify entry points when assets are undervalued, as the company's capitalization is based on the development of breakthrough epigenetic drugs for targeted gene management in the therapy of viral forms of cancer.
Who Viracta Therapeutics competes with
ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye)|Price-to-Revenue Ratio Veru Pharma (VERU)|P/S Multiple Tempest Tx (TPST)|Price-to-Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Revenue Ratio|Mural Oncology - P/S Multiple|KAPA - P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Revenue Ratio|Market Cap to Revenue CytoMed|Price-to-Revenue Ratio curis.com|Market Cap to Revenue Apollomics, Inc. (APLM)|P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Genprex GNPX|Price-to-Revenue Coefficient Calidi Bio (CLDI)|sunshinebiopharma.com - P/S Multiple|Price to Sales xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Revenue Ratio|Purple Biotech Ltd. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio AON|P/S Multiple BeiGene Ltd.|Price-to-Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Market Cap to Revenue Elevation Oncology, Inc. ELEV|P/S Multiple ICAD (iCAD Inc.)|IKNA - Market Cap to Revenue|NTBL: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd
